The present invention relates to a novel biomarker for diagnosis and treatment of antihormonal resistance and triple-negative breast cancer, and a composition comprising the same. More particularly, the present invention relates to a novel biomarker and a composition comprising the same, Hormone therapy in anti-hormone-refractory breast cancer including triple-negative breast cancer by allowing the effective diagnosis of anti-hormone and triple-negative breast cancer and further increasing expression of Mel-18 gene or administration of Mel-18 protein The present invention can provide a pharmaceutical composition capable of dramatically improving the therapeutic efficacy of the present invention.
展开▼
